

**Supplementary Table S1. Studies analyzed.**

CV=cardiovascular, GFR=glomerular filtration rate, HCTZ=hydrocholothiazide, metformin-XR=metformin extended release, OAD=oral antidiabetic drug, TZD=thiazolidinedione.

<b>Study</b>	<b>Duration analyzed, weeks</b>	<b>Treatment arms</b>	<b>Background therapy</b>
Phase 2 dose-range monotherapy	12	Dapagliflozin 2.5, 5, 10, 20, 50 mg, placebo, metformin-XR 750/1500 mg	Treatment-naïve
Phase 2 monotherapy (Japanese population)	12	Dapagliflozin 1, 2.5, 5, 10 mg, placebo	Treatment-naïve
Phase 2 add-on to metformin, Effect on GFR	12	Dapagliflozin 10 mg, HCTZ 25 mg, or placebo	Metformin ± sulphonylurea
Phase 2 add-on to metformin ± insulin secretagogue, Insulin sensitivity	12	Dapagliflozin 5 mg, placebo	Metformin ± insulin secretagogue
Phase 3 monotherapy (Japanese population)	24	Dapagliflozin 5, 10 mg, placebo	Treatment-naïve
Low dose monotherapy	24	Dapagliflozin 1, 2.5, 5 mg	Treatment-naïve
Phase 3 monotherapy	24 + 78	Dapagliflozin 2.5, 5, 10 mg, placebo	Treatment-naïve
Phase 3 Asia monotherapy	24	Dapagliflozin 5, 10 mg, placebo	Treatment-naïve
Add-on to metformin	24 + 78	Dapagliflozin 2.5, 5, 10 mg, placebo	Metformin ≥1500 mg/day
Add-on to metformin, (Primary endpoint – body weight)	24 +78	Dapagliflozin 10 mg, placebo	Metformin ≥1500 mg/day
Initial combination with metformin	24	Dapagliflozin 5 mg + metformin-XR, Dapagliflozin 5 mg, metformin-XR up to 2000 mg	Treatment-naïve
Initial combination with metformin	24	Dapagliflozin 10 mg + metformin-XR, Dapagliflozin 10 mg, metformin-XR up to 2000 mg	Treatment-naïve
Add-on to metformin vs glipizide	52 + 52 + 104	Dapagliflozin 2.5, 5, 10 mg, glipizide	Metformin ≥ 1500 mg/day
Add-on to sulphonylurea	24 + 24	Dapagliflozin 2.5, 5, 10 mg, placebo	Glimepiride 4 mg/day
Add-on to TZD	24 + 24	Dapagliflozin 5, 10 mg, placebo	Pioglitazone 30 or 45 mg/day
Add-on to sitagliptin	24 + 24	Dapagliflozin 10 mg, placebo	Sitagliptin 100 mg/day ± metformin ≥1500 mg/day

Add-on to insulin	12	Dapagliflozin 10, 20 mg, placebo	Insulin sensitizers (metformin ± TZDs) + 50% original INS
Add-on to insulin	24 + 24 + 56	Dapagliflozin 2.5, 5, 10 mg, placebo	Insulin ≥30 IU/day ± maximum 2 OADs
High CV risk add-on to usual care	24 + 28 + 52	Dapagliflozin 10 mg, placebo	OADs ± insulin
High CV risk add-on to usual care	24 + 28 + 52	Dapagliflozin 10 mg, placebo	OADs ± insulin
Moderate renal impairment	24 + 28 + 52	Dapagliflozin 5, 10 mg, placebo	Any except metformin